New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies

Author： Pimentel Agustin Velez Michel Barahona Luz J Swords Ronan Lekakis Lazaros

ISSN： 1479-6694

Source： Future Oncology, Vol.9, Iss.5, 2013-05, pp. : 681-697

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

By Karp Judith Lancet Jeffrey

Cancer Investigation, Vol. 25, Iss. 6, 2007-09 ,pp. : 484-494

Informa Healthcare

Access to resources Recommend Favorite

Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies

By Karp Judith E Lancet Jeffrey E

Future Oncology, Vol. 1, Iss. 6, 2005-12 ,pp. : 719-731

Future Medicine

Access to resources Recommend Favorite

HEMATOLOGIC MALIGNANCIES

Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. : 33-47

Informa Healthcare

Access to resources Recommend Favorite

The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 5, 2009-06 ,pp. : 550-559

Bentham Science Publishers

Access to resources Recommend Favorite

Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 2, Iss. 3, 2002-01 ,pp. : 387-401

Bentham Science Publishers

Access to resources Recommend Favorite